Introduction

The management of type 2 diabetes (T2D) has been transformed by the advent of glucagon-like peptide-1 (GLP-1) receptor agonists. Among these, semaglutide has emerged as a particularly effective agent, offering benefits that extend beyond glycemic control to include substantial weight reduction and cardiovascular risk mitigation. Wegovy, a once-weekly injectable formulation of semaglutide developed by Novo Nordisk, was initially approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition. However, its pharmacological profile and clinical evidence have positioned it as a key option in the broader diabetes care landscape. This article provides a comprehensive examination of Wegovy's pharmacology, mechanism of action, clinical utility in diabetes, safety considerations, and practical prescribing insights.

What Is Wegovy?

Wegovy is a once-weekly subcutaneous injection containing semaglutide, a synthetic analog of the human GLP-1 hormone. It is produced by Novo Nordisk and was granted FDA approval for weight management in June 2021. While its sister drug Ozempic (also semaglutide, at a lower dose) is specifically indicated for glycemic control in T2D, Wegovy is approved for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater (obesity) or 27 kg/m² or greater (overweight) with at least one weight-related condition such as hypertension, dyslipidemia, or type 2 diabetes. Importantly, Wegovy is also used off-label and in clinical practice for glycemic control in patients with T2D, given that its active ingredient is identical to Ozempic. The distinction lies in the dosing: Wegovy uses a higher maintenance dose (2.4 mg once weekly) compared with Ozempic (up to 1.0 mg or 2.0 mg once weekly).

The Pharmacological Mechanism of Semaglutide

GLP-1 Receptor Agonism

Semaglutide is a long-acting GLP-1 receptor agonist (GLP-1 RA). GLP-1 is an incretin hormone secreted by L-cells in the distal ileum and colon in response to nutrient ingestion. Under physiological conditions, GLP-1 has a very short half-life (1–2 minutes) due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). Semaglutide is structurally modified to resist DPP-4 cleavage and to bind albumin, resulting in a prolonged half-life of approximately one week. By activating GLP-1 receptors distributed in the pancreas, brain, gastrointestinal tract, heart, and other tissues, semaglutide produces pleiotropic effects.

Pharmacodynamics: Key Physiological Effects

Glucose-dependent insulin secretion: In pancreatic beta-cells, GLP-1 receptor activation stimulates insulin release only when blood glucose levels are elevated. This glucose-dependent mechanism reduces the risk of hypoglycemia, a significant advantage over sulfonylureas or insulin.

Suppression of glucagon secretion: GLP-1 receptor activation in alpha-cells suppresses glucagon release, reducing hepatic glucose output and further lowering fasting and postprandial glucose.

Delayed gastric emptying: GLP-1 agonism slows gastric motility, which slows the absorption of nutrients, blunts postprandial glucose spikes, and contributes to early satiety.

Central appetite regulation: Semaglutide acts on GLP-1 receptors in the hypothalamus and brainstem, particularly the arcuate nucleus and nucleus tractus solitarius, to promote satiety and reduce hunger. This central effect is believed to be a major driver of the substantial weight loss observed with higher doses.

Cardiovascular and anti-inflammatory effects: GLP-1 receptor agonism has been associated with improved endothelial function, reduced oxidative stress, and attenuation of inflammatory markers. These effects likely contribute to the cardiovascular risk reduction seen in major outcome trials.

Pharmacokinetics

Semaglutide has a molecular structure that includes a fatty acid side chain (C18 diacid) which binds strongly to albumin, allowing for once-weekly dosing. After subcutaneous administration, peak plasma concentrations occur after 24–48 hours. The terminal half-life is approximately 1 week (7 days), supporting steady-state levels after 4–5 weekly doses. Absorption is slow and prolonged, with an absolute bioavailability of about 89%. Food does not significantly affect absorption. The drug is not extensively metabolized; it is primarily eliminated via the kidneys (about 6–7% as unchanged drug). No dose adjustment is required for mild or moderate renal impairment, but caution is advised in severe renal impairment (eGFR <15 mL/min/1.73 m²) as clinical experience is limited.

Wegovy in the Management of Type 2 Diabetes

Glycemic Control

Semaglutide at Wegovy doses (up to 2.4 mg weekly) produces clinically meaningful reductions in hemoglobin A1c (HbA1c). In the STEP 2 trial, which enrolled patients with T2D and overweight or obesity, semaglutide 2.4 mg reduced HbA1c by 1.6% from baseline (compared with 0.4% with placebo). The glucose-lowering effect is mediated by enhanced insulin secretion, suppressed glucagon, and delayed gastric emptying. In addition, the weight loss achieved with Wegovy improves insulin sensitivity, further contributing to glycemic improvements.

Weight Reduction

Weight loss is a key therapeutic goal in T2D, as excess body weight exacerbates insulin resistance and cardiovascular risk. Wegovy has demonstrated consistent superior weight reduction compared with placebo and active comparators. In the STEP 1 trial (patients without diabetes), mean weight loss was 14.9% of baseline weight at 68 weeks. For patients with T2D (STEP 2), the mean weight loss was 9.6% (vs. 3.4% with placebo and 7.0% with semaglutide 1.0 mg once weekly). The weight loss is driven primarily by reduced caloric intake due to centrally mediated appetite suppression and delayed gastric emptying. The degree of weight loss is dose-dependent and sustained over the treatment period.

Cardiovascular Benefits

The cardiovascular safety and efficacy of semaglutide have been established in the SELECT trial (for weight management without diabetes) and the SUSTAIN 6 trial (for T2D). SUSTAIN 6 demonstrated that semaglutide (0.5 mg or 1.0 mg weekly) reduced the risk of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 26% compared with placebo in patients with T2D and established cardiovascular disease or chronic kidney disease. The SELECT trial, which enrolled patients with overweight or obesity and preexisting cardiovascular disease but without diabetes, showed a 20% reduction in MACE with semaglutide 2.4 mg weekly. These benefits appear to be independent of the glucose-lowering and weight-loss effects, suggesting direct cardioprotective mechanisms. Wegovy is thus indicated for reducing the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as per the FDA label update in March 2024.

Comparison with Other GLP-1 Receptor Agonists

Wegovy (semaglutide 2.4 mg) provides greater weight reduction than liraglutide (Saxenda, 3.0 mg daily) and dulaglutide (Trulicity). In terms of glycemic efficacy, semaglutide is comparable to or slightly superior to dulaglutide and liraglutide. However, the weight loss difference is more pronounced: for example, in the STEP 8 trial, semaglutide 2.4 mg produced a 15.8% weight loss versus 6.4% with liraglutide 3.0 mg over 68 weeks. Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, has shown even greater weight loss and glycemic reductions in head-to-head trials, but Wegovy remains a powerful option with robust cardiovascular outcome data.

Clinical Evidence Supporting Wegovy

Wegovy's efficacy and safety are underpinned by the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program, as well as data from SUSTAIN and SELECT.

  • STEP 1: 68-week, double-blind, placebo-controlled trial in 1,961 adults with obesity (BMI ≥30) or overweight (≥27) with one weight-related comorbidity, without diabetes. Mean weight loss: 14.9% vs. 2.4% with placebo. (NEJM, 2021)
  • STEP 2: 68-week trial in 1,210 adults with T2D and BMI ≥27. Mean weight loss: 9.6% vs. 3.4% with placebo, and HbA1c reduction -1.6% vs. -0.4%. (The Lancet, 2021)
  • STEP 8: Head-to-head with liraglutide 3.0 mg. Semaglutide 2.4 mg achieved significantly greater weight loss (15.8% vs. 6.4%). (JAMA, 2022)
  • SUSTAIN 6: Cardiovascular outcomes trial in T2D patients with high CV risk. Semaglutide 0.5/1.0 mg reduced MACE by 26% (HR 0.74, 95% CI 0.58–0.95). (NEJM, 2016)
  • SELECT: Cardiovascular outcomes trial in 17,604 adults with overweight/obesity and preexisting CVD but without diabetes. Semaglutide 2.4 mg reduced MACE by 20% (HR 0.80, 95% CI 0.72–0.90). (NEJM, 2023)

Dosing and Administration

Wegovy is supplied as a single-dose prefilled pen delivering 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, or 2.4 mg doses. The dosing schedule involves a gradual dose escalation over 16–20 weeks to mitigate gastrointestinal side effects. The starting dose is 0.25 mg once weekly for 4 weeks, then increased to 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, then 1.7 mg for 4 weeks, and finally to the maintenance dose of 2.4 mg once weekly. If patients cannot tolerate the 2.4 mg maintenance dose after several weeks, a temporary reduction to 1.7 mg may be considered, but full efficacy data are available only for the 2.4 mg dose. The injection is administered subcutaneously in the abdomen, thigh, or upper arm, on the same day each week, with or without food.

Safety Profile and Side Effects

The most common side effects of Wegovy are gastrointestinal, related to its mechanism of action on gastric emptying and central satiety. Nausea, vomiting, diarrhea, constipation, and abdominal pain occur frequently, especially during dose escalation. Nausea is reported in up to 44% of patients, though it tends to diminish over time. Slow dose titration and taking the injection with a low-fat meal can help mitigate symptoms. Serious adverse events include:

  • Pancreatitis: GLP-1 receptor agonists have been associated with acute pancreatitis, though causality is not definitively established. Patients should be educated to seek medical attention for persistent severe abdominal pain. Discontinue Wegovy if pancreatitis is suspected.
  • Gallbladder disease: Weight loss of any cause is linked to an increased risk of cholelithiasis. In STEP trials, cholecystitis and cholelithiasis were more common with semaglutide than placebo (about 1.5% vs. 0.5%).
  • Thyroid C-cell tumors: In rodent studies, semaglutide caused dose-dependent and duration-dependent increases in calcitonin and incidence of medullary thyroid carcinoma (MTC). Human data are limited but show a slight increase in calcitonin levels; however, no cases of MTC have been reported in clinical trials. Wegovy is contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Diabetic retinopathy: Rapid improvement in glycemic control can transiently worsen diabetic retinopathy. In SUSTAIN 6, semaglutide was associated with an increased risk of retinal complications (HR 1.76), primarily in patients with preexisting retinopathy and rapid HbA1c reduction. Baseline and periodic retinal exams are recommended.
  • Hypoglycemia: When used alone, the risk of hypoglycemia is low. However, when combined with insulin or sulfonylureas, the risk increases. In such cases, clinicians should consider reducing the dose of the concomitant secretagogue or insulin.
  • Acute kidney injury: Severe GI side effects leading to volume depletion may cause acute kidney injury, particularly in patients with preexisting renal impairment. Monitor renal function during dose initiation and after significant GI adverse events.

Contraindications and Precautions

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. It is also contraindicated during pregnancy, as weight loss is not recommended and the drug has potential fetal risk based on animal studies. Women of childbearing age should use effective contraception and discontinue Wegovy at least 2 months before planned pregnancy. Other contraindications include severe hypersensitivity to semaglutide or any product components, and a history of pancreatitis (relative caution). Caution should be exercised in patients with gastroparesis, as semaglutide can worsen gastric stasis.

Monitoring and Patient Education

Healthcare providers should conduct baseline assessments including BMI, glycemic parameters (HbA1c, fasting glucose), renal function, and a fundoscopic eye exam for patients with diabetes. During treatment, monitor for tolerance of GI side effects, weight loss trajectory, glycemic improvement, and signs of pancreatitis (persistent severe abdominal pain with or without vomiting). Patients should be counseled on injection technique, proper storage (refrigerate or room temperature for up to 28 days), and the importance of adhering to the dose escalation schedule. They should be instructed to discontinue Wegovy and seek immediate medical attention for symptoms of acute pancreatitis (severe abdominal pain radiating to the back). For patients with T2D, advise that Wegovy is not a substitute for insulin if insulin deficiency is present. Additionally, patients should be aware that weight regain is likely after discontinuation, so lifestyle modifications (diet and physical activity) should be reinforced throughout treatment.

Conclusion

The pharmacology of Wegovy (semaglutide 2.4 mg) is rooted in its potent GLP-1 receptor agonism, which produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction. In the context of diabetes, Wegovy offers robust glycemic control, substantial weight loss, and proven cardiovascular benefits, making it a valuable addition to the therapeutic armamentarium. Its once-weekly dosing and favorable safety profile, when properly managed, support long-term adherence. As obesity and type 2 diabetes remain pressing global health challenges, Wegovy stands as a pharmacologically well-characterized, evidence-based option for improving metabolic and cardiovascular outcomes. Clinicians should remain informed about updated guidelines, monitor for potential adverse effects, and engage in shared decision-making to optimize patient outcomes.